ArticleOncotarget2017

Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.

Levent Dizdar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.